Chemical Information
Antiviral agent ID	DrugRepV_7696
Antiviral agent name	Immunoglobulin F(ab’)2
Structural Information
2-D Structure is not available	3-D Structure is not available
Clinical Information
Biological Information
Secondary Indication	SARS Coronavirus-2 (SARS-CoV-2) 2
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Drug concentration)	0.07 μg/ml
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Reference	Pan X, Zhou P, Fan T, Wu Y, Zhang J, Shi X, Shang W, Fang L, Jiang X, Shi J, Sun Y, Zhao S, Gong R, Chen Z, Xiao G..Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro..Antiviral Res. 2020 Jul 10:104868. doi: 10.1016/j.antiviral.2020.104868. PMID: 32659292; PMCID: PMC7 PMID:32659292
Comment	RBD-specific F(ab’) fragments neutralized SARS-CoV-2 with an EC80 of 0.18 μg/ml.